Higher revenues from its Auryon and AngioVac platforms helped interventional technology developer AngioDynamics to achieve a 2% increase in net sales in its 2021 fiscal third quarter despite ongoing headwinds from the COVID-19 pandemic.
For the period (end-February 28), AngioDynamics had net sales of $71.2 million, up from $69.8 million from the same quarter a year ago. The company had a third-quarter net loss of $3.5 million, compared with a net loss of $5.7 million last year.
In other developments, AngioDynamics increased its guidance for the 2021 fiscal year. The firm said it now expects to produce net sales between $285 million to $288 million, up from previous projections of $278 million to $284 million.
